These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31467428)

  • 1. Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation.
    Kint NG; Heylen E; Pepe D; De Keersmaecker K; Verfaillie CM; Delforge M
    Leukemia; 2020 Feb; 34(2):651-655. PubMed ID: 31467428
    [No Abstract]   [Full Text] [Related]  

  • 2. Carfilzomib.
    Kortuem KM; Stewart AK
    Blood; 2013 Feb; 121(6):893-7. PubMed ID: 23393020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib (Kyprolis°) in multiple myeloma.
    Prescrire Int; 2017 May; 26(182):120. PubMed ID: 30730668
    [No Abstract]   [Full Text] [Related]  

  • 5. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
    Vandross A
    Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib: a rare cause of posterior reversible encephalopathy syndrome.
    Katz-Agranov N; Padilla J; Scoon J; Cherian SV
    Ann Hematol; 2016 Oct; 95(11):1923-4. PubMed ID: 27477479
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple myeloma: new uses for available agents, excitement for the future.
    Anderson KC
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):694-6. PubMed ID: 25995433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience.
    Uysal A; Akad Soyer N; Özkan M; Şahin F; Vural F; Töbü M; Tombuloğlu M; Saydam G
    Turk J Med Sci; 2018 Feb; 48(1):80-83. PubMed ID: 29479960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
    Moreau P
    Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors.
    Mendonca NP; Kadayakkara DK; Forde IC; Rudkovskaia A; Saul ZK; Lobo DJ
    Am J Case Rep; 2016 Feb; 17():76-8. PubMed ID: 26861506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib in multiple myeloma.
    Andreu-Vieyra C; Berenson JR
    Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.
    Shen X; Wu C; Lei M; Yan Q; Zhang H; Zhang L; Wang X; Yang Y; Li J; Zhu Y; Chen L
    Cell Death Dis; 2021 Apr; 12(5):429. PubMed ID: 33931582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib-Based 3-Drug Regimens for Newly Diagnosed Multiple Myeloma-All That Glitters Is Not Gold.
    Hashmi H; Shah Z; Anwer F
    JAMA Oncol; 2021 Jul; 7(7):967-968. PubMed ID: 33792618
    [No Abstract]   [Full Text] [Related]  

  • 20. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.